Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well‐established, and the impact of its use in different treatment settings is not clear. We aimed to report...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2023-05, Vol.98 (5), p.750-759 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 759 |
|---|---|
| container_issue | 5 |
| container_start_page | 750 |
| container_title | American journal of hematology |
| container_volume | 98 |
| creator | Arulogun, Suzanne O. Brian, Duncan Goradia, Harshita Cooney, Aaron Menne, Tobias Koo, RayMun O'Neill, Aideen T. Vos, Josephine M. I. Pratt, Guy Turner, Deborah Marshall, Kirsty Manos, Kate Anderson, Claire Gavriatopoulou, Maria Kyriakou, Charalampia Kersten, Marie J. Minnema, Monique C. Koutoumanou, Eirini El‐Sharkawi, Dima Linton, Kim Talaulikar, Dipti McCarthy, Helen Bishton, Mark Follows, George Wechalekar, Ashutosh D'Sa, Shirley P. |
| description | Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well‐established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p |
| doi_str_mv | 10.1002/ajh.26895 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2783498140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2783498140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3885-f41ee164bc4223f039b8b97ac578dc89a207b259dc6afc4afa3db20a03292aac3</originalsourceid><addsrcrecordid>eNp10c1OFTEYBuDGaOQILLwB08QNLg70Z6andYcEQYORhYbl5GunAz2ZTo_9CbDmnrgBb4x6DhJi4qpdPN_b5nsRekvJPiWEHcDyap8JqdoXaEaJEnMpWvYSzQgXtN6J2kJvUloSQmkjyWu0xYUUQrF2hu4-2akHX1J2k8WrsSQcXS43zoPGQ4g4X1mco4Xs7ZRxGPAFjL2dUo6_7z3-BiaGyzHoMtZ57-AjPofs1rRkE7xNGKYeO78Csx7Xz9_rQ3LT5Q56NcCY7O7juY1-fj7-cXQ6P_t-8uXo8GxuuJTtfGiotVQ02jSM8YFwpaVWCzDtQvZGKmBkoVmreiNgMA0MwHvNCBDOFAMwfBvtbXJXMfwqNuXOu2TsOMJkQ0kdW0jeKEkbUun7f-gylDjV31Wl6m9aSXhVHzaqLiGlaIduFevi4m1HSfenma42062bqfbdY2LR3vZP8m8VFRxswLUb7e3_k7rDr6ebyAeFK5sv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2798855803</pqid></control><display><type>article</type><title>Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing</title><source>MEDLINE</source><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Arulogun, Suzanne O. ; Brian, Duncan ; Goradia, Harshita ; Cooney, Aaron ; Menne, Tobias ; Koo, RayMun ; O'Neill, Aideen T. ; Vos, Josephine M. I. ; Pratt, Guy ; Turner, Deborah ; Marshall, Kirsty ; Manos, Kate ; Anderson, Claire ; Gavriatopoulou, Maria ; Kyriakou, Charalampia ; Kersten, Marie J. ; Minnema, Monique C. ; Koutoumanou, Eirini ; El‐Sharkawi, Dima ; Linton, Kim ; Talaulikar, Dipti ; McCarthy, Helen ; Bishton, Mark ; Follows, George ; Wechalekar, Ashutosh ; D'Sa, Shirley P.</creator><creatorcontrib>Arulogun, Suzanne O. ; Brian, Duncan ; Goradia, Harshita ; Cooney, Aaron ; Menne, Tobias ; Koo, RayMun ; O'Neill, Aideen T. ; Vos, Josephine M. I. ; Pratt, Guy ; Turner, Deborah ; Marshall, Kirsty ; Manos, Kate ; Anderson, Claire ; Gavriatopoulou, Maria ; Kyriakou, Charalampia ; Kersten, Marie J. ; Minnema, Monique C. ; Koutoumanou, Eirini ; El‐Sharkawi, Dima ; Linton, Kim ; Talaulikar, Dipti ; McCarthy, Helen ; Bishton, Mark ; Follows, George ; Wechalekar, Ashutosh ; D'Sa, Shirley P.</creatorcontrib><description>Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well‐established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p < 0.001). Depth of response impacted survival outcomes: two‐year predicted PFS rates after achieving CR/VGPR vs PR were 96% versus 82%, respectively (p = 0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000 mg/m2 compared with those receiving 800–999 mg/m2 (p = 0.04). In the relapsed cohort, those who received doses of <600 mg/m2 had poorer PFS outcomes compared with those who received ≥600 mg/m2 (p = 0.02). Attaining CR/VGPR following BR results in superior survival, and total bendamustine dose significantly impacts response and survival outcomes, in both frontline and relapsed settings.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.26895</identifier><identifier>PMID: 36866925</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Antineoplastic Combined Chemotherapy Protocols ; Bendamustine Hydrochloride - therapeutic use ; Dosage ; Hematology ; Humans ; Immunotherapy ; Macroglobulinemia ; Monoclonal antibodies ; Neoplasm Recurrence, Local - drug therapy ; Retrospective Studies ; Rituximab ; Rituximab - therapeutic use ; Survival ; Treatment Outcome ; Waldenstrom Macroglobulinemia - drug therapy</subject><ispartof>American journal of hematology, 2023-05, Vol.98 (5), p.750-759</ispartof><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3885-f41ee164bc4223f039b8b97ac578dc89a207b259dc6afc4afa3db20a03292aac3</citedby><cites>FETCH-LOGICAL-c3885-f41ee164bc4223f039b8b97ac578dc89a207b259dc6afc4afa3db20a03292aac3</cites><orcidid>0000-0002-3139-8379 ; 0000-0001-5151-4990 ; 0000-0001-6058-1036</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.26895$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.26895$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36866925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arulogun, Suzanne O.</creatorcontrib><creatorcontrib>Brian, Duncan</creatorcontrib><creatorcontrib>Goradia, Harshita</creatorcontrib><creatorcontrib>Cooney, Aaron</creatorcontrib><creatorcontrib>Menne, Tobias</creatorcontrib><creatorcontrib>Koo, RayMun</creatorcontrib><creatorcontrib>O'Neill, Aideen T.</creatorcontrib><creatorcontrib>Vos, Josephine M. I.</creatorcontrib><creatorcontrib>Pratt, Guy</creatorcontrib><creatorcontrib>Turner, Deborah</creatorcontrib><creatorcontrib>Marshall, Kirsty</creatorcontrib><creatorcontrib>Manos, Kate</creatorcontrib><creatorcontrib>Anderson, Claire</creatorcontrib><creatorcontrib>Gavriatopoulou, Maria</creatorcontrib><creatorcontrib>Kyriakou, Charalampia</creatorcontrib><creatorcontrib>Kersten, Marie J.</creatorcontrib><creatorcontrib>Minnema, Monique C.</creatorcontrib><creatorcontrib>Koutoumanou, Eirini</creatorcontrib><creatorcontrib>El‐Sharkawi, Dima</creatorcontrib><creatorcontrib>Linton, Kim</creatorcontrib><creatorcontrib>Talaulikar, Dipti</creatorcontrib><creatorcontrib>McCarthy, Helen</creatorcontrib><creatorcontrib>Bishton, Mark</creatorcontrib><creatorcontrib>Follows, George</creatorcontrib><creatorcontrib>Wechalekar, Ashutosh</creatorcontrib><creatorcontrib>D'Sa, Shirley P.</creatorcontrib><title>Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well‐established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p < 0.001). Depth of response impacted survival outcomes: two‐year predicted PFS rates after achieving CR/VGPR vs PR were 96% versus 82%, respectively (p = 0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000 mg/m2 compared with those receiving 800–999 mg/m2 (p = 0.04). In the relapsed cohort, those who received doses of <600 mg/m2 had poorer PFS outcomes compared with those who received ≥600 mg/m2 (p = 0.02). Attaining CR/VGPR following BR results in superior survival, and total bendamustine dose significantly impacts response and survival outcomes, in both frontline and relapsed settings.</description><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Bendamustine Hydrochloride - therapeutic use</subject><subject>Dosage</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Macroglobulinemia</subject><subject>Monoclonal antibodies</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Waldenstrom Macroglobulinemia - drug therapy</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10c1OFTEYBuDGaOQILLwB08QNLg70Z6andYcEQYORhYbl5GunAz2ZTo_9CbDmnrgBb4x6DhJi4qpdPN_b5nsRekvJPiWEHcDyap8JqdoXaEaJEnMpWvYSzQgXtN6J2kJvUloSQmkjyWu0xYUUQrF2hu4-2akHX1J2k8WrsSQcXS43zoPGQ4g4X1mco4Xs7ZRxGPAFjL2dUo6_7z3-BiaGyzHoMtZ57-AjPofs1rRkE7xNGKYeO78Csx7Xz9_rQ3LT5Q56NcCY7O7juY1-fj7-cXQ6P_t-8uXo8GxuuJTtfGiotVQ02jSM8YFwpaVWCzDtQvZGKmBkoVmreiNgMA0MwHvNCBDOFAMwfBvtbXJXMfwqNuXOu2TsOMJkQ0kdW0jeKEkbUun7f-gylDjV31Wl6m9aSXhVHzaqLiGlaIduFevi4m1HSfenma42062bqfbdY2LR3vZP8m8VFRxswLUb7e3_k7rDr6ebyAeFK5sv</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Arulogun, Suzanne O.</creator><creator>Brian, Duncan</creator><creator>Goradia, Harshita</creator><creator>Cooney, Aaron</creator><creator>Menne, Tobias</creator><creator>Koo, RayMun</creator><creator>O'Neill, Aideen T.</creator><creator>Vos, Josephine M. I.</creator><creator>Pratt, Guy</creator><creator>Turner, Deborah</creator><creator>Marshall, Kirsty</creator><creator>Manos, Kate</creator><creator>Anderson, Claire</creator><creator>Gavriatopoulou, Maria</creator><creator>Kyriakou, Charalampia</creator><creator>Kersten, Marie J.</creator><creator>Minnema, Monique C.</creator><creator>Koutoumanou, Eirini</creator><creator>El‐Sharkawi, Dima</creator><creator>Linton, Kim</creator><creator>Talaulikar, Dipti</creator><creator>McCarthy, Helen</creator><creator>Bishton, Mark</creator><creator>Follows, George</creator><creator>Wechalekar, Ashutosh</creator><creator>D'Sa, Shirley P.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3139-8379</orcidid><orcidid>https://orcid.org/0000-0001-5151-4990</orcidid><orcidid>https://orcid.org/0000-0001-6058-1036</orcidid></search><sort><creationdate>202305</creationdate><title>Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing</title><author>Arulogun, Suzanne O. ; Brian, Duncan ; Goradia, Harshita ; Cooney, Aaron ; Menne, Tobias ; Koo, RayMun ; O'Neill, Aideen T. ; Vos, Josephine M. I. ; Pratt, Guy ; Turner, Deborah ; Marshall, Kirsty ; Manos, Kate ; Anderson, Claire ; Gavriatopoulou, Maria ; Kyriakou, Charalampia ; Kersten, Marie J. ; Minnema, Monique C. ; Koutoumanou, Eirini ; El‐Sharkawi, Dima ; Linton, Kim ; Talaulikar, Dipti ; McCarthy, Helen ; Bishton, Mark ; Follows, George ; Wechalekar, Ashutosh ; D'Sa, Shirley P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3885-f41ee164bc4223f039b8b97ac578dc89a207b259dc6afc4afa3db20a03292aac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Bendamustine Hydrochloride - therapeutic use</topic><topic>Dosage</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Macroglobulinemia</topic><topic>Monoclonal antibodies</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Waldenstrom Macroglobulinemia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arulogun, Suzanne O.</creatorcontrib><creatorcontrib>Brian, Duncan</creatorcontrib><creatorcontrib>Goradia, Harshita</creatorcontrib><creatorcontrib>Cooney, Aaron</creatorcontrib><creatorcontrib>Menne, Tobias</creatorcontrib><creatorcontrib>Koo, RayMun</creatorcontrib><creatorcontrib>O'Neill, Aideen T.</creatorcontrib><creatorcontrib>Vos, Josephine M. I.</creatorcontrib><creatorcontrib>Pratt, Guy</creatorcontrib><creatorcontrib>Turner, Deborah</creatorcontrib><creatorcontrib>Marshall, Kirsty</creatorcontrib><creatorcontrib>Manos, Kate</creatorcontrib><creatorcontrib>Anderson, Claire</creatorcontrib><creatorcontrib>Gavriatopoulou, Maria</creatorcontrib><creatorcontrib>Kyriakou, Charalampia</creatorcontrib><creatorcontrib>Kersten, Marie J.</creatorcontrib><creatorcontrib>Minnema, Monique C.</creatorcontrib><creatorcontrib>Koutoumanou, Eirini</creatorcontrib><creatorcontrib>El‐Sharkawi, Dima</creatorcontrib><creatorcontrib>Linton, Kim</creatorcontrib><creatorcontrib>Talaulikar, Dipti</creatorcontrib><creatorcontrib>McCarthy, Helen</creatorcontrib><creatorcontrib>Bishton, Mark</creatorcontrib><creatorcontrib>Follows, George</creatorcontrib><creatorcontrib>Wechalekar, Ashutosh</creatorcontrib><creatorcontrib>D'Sa, Shirley P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arulogun, Suzanne O.</au><au>Brian, Duncan</au><au>Goradia, Harshita</au><au>Cooney, Aaron</au><au>Menne, Tobias</au><au>Koo, RayMun</au><au>O'Neill, Aideen T.</au><au>Vos, Josephine M. I.</au><au>Pratt, Guy</au><au>Turner, Deborah</au><au>Marshall, Kirsty</au><au>Manos, Kate</au><au>Anderson, Claire</au><au>Gavriatopoulou, Maria</au><au>Kyriakou, Charalampia</au><au>Kersten, Marie J.</au><au>Minnema, Monique C.</au><au>Koutoumanou, Eirini</au><au>El‐Sharkawi, Dima</au><au>Linton, Kim</au><au>Talaulikar, Dipti</au><au>McCarthy, Helen</au><au>Bishton, Mark</au><au>Follows, George</au><au>Wechalekar, Ashutosh</au><au>D'Sa, Shirley P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>98</volume><issue>5</issue><spage>750</spage><epage>759</epage><pages>750-759</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><abstract>Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well‐established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p < 0.001). Depth of response impacted survival outcomes: two‐year predicted PFS rates after achieving CR/VGPR vs PR were 96% versus 82%, respectively (p = 0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000 mg/m2 compared with those receiving 800–999 mg/m2 (p = 0.04). In the relapsed cohort, those who received doses of <600 mg/m2 had poorer PFS outcomes compared with those who received ≥600 mg/m2 (p = 0.02). Attaining CR/VGPR following BR results in superior survival, and total bendamustine dose significantly impacts response and survival outcomes, in both frontline and relapsed settings.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>36866925</pmid><doi>10.1002/ajh.26895</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3139-8379</orcidid><orcidid>https://orcid.org/0000-0001-5151-4990</orcidid><orcidid>https://orcid.org/0000-0001-6058-1036</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2023-05, Vol.98 (5), p.750-759 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2783498140 |
| source | MEDLINE; Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols Bendamustine Hydrochloride - therapeutic use Dosage Hematology Humans Immunotherapy Macroglobulinemia Monoclonal antibodies Neoplasm Recurrence, Local - drug therapy Retrospective Studies Rituximab Rituximab - therapeutic use Survival Treatment Outcome Waldenstrom Macroglobulinemia - drug therapy |
| title | Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T10%3A49%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bendamustine%20plus%20rituximab%20for%20the%20treatment%20of%20Waldenstr%C3%B6m%20Macroglobulinemia:%20Patient%20outcomes%20and%20impact%20of%20bendamustine%20dosing&rft.jtitle=American%20journal%20of%20hematology&rft.au=Arulogun,%20Suzanne%20O.&rft.date=2023-05&rft.volume=98&rft.issue=5&rft.spage=750&rft.epage=759&rft.pages=750-759&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.26895&rft_dat=%3Cproquest_cross%3E2783498140%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2798855803&rft_id=info:pmid/36866925&rfr_iscdi=true |